[1]丛严东. 治疗药物监测在临床用药中的应用价值[J]. 中国药物经济学, 2016,11(02): 31-32.
[2]程道海, 陆华, 刘滔滔, 等. 我国治疗药物监测的现状与展望[J]. 广西医科大学学报, 2016,33(05): 910-913.
[3]SANDERS G D, NEUMANN P J, BASU A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine[J]. JAMA, 2016,316(10): 1093-1103.
[4]SACKETT D L, ROSENBERG W M, GRAY J A, et al. Evidence based medicine: what it is and what it isn't[J]. BMJ, 1996,312(7023): 71-72.
[5]MAUSKOPF J A, SULLIVAN S D, ANNEMANS L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis[J]. Value Health, 2007,10(5): 336-347.
[6]ANGELIS A, LANGE A, KANAVOS P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries[J]. Eur J Health Econ, 2018,19(1): 123-152.
[7]WOUTERS O J, NACI H, SAMANI N J. QALYs in cost-effectiveness analysis: an overview for cardiologists[J]. Heart, 2015,101(23): 1868-1873.
[8]PALTZER J, BARKER E, WITT W P. Measuring the health-related quality of life (HRQoL) of young children in resource-limited settings: a review of existing measures[J]. Qual Life Res, 2013,22(6): 1177-1187.
[9]THOKALA P, DUENAS A. Multiple criteria decision analysis for health technology assessment[J]. Value Health, 2012,15(8): 1172-1181.
[10]HSU J C, LIN J Y, LIN P C, et al. Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment[J]. PLoS One, 2019,14(12): e225938.
[11]胡善联, 杨燕, 何江江, 等. 罕见病孤儿药遴选标准的多维决策分析[J]. 中国卫生经济, 2018,37(03): 67-70.
[12]RUTTEN-VAN M M, LEIJTEN F, HOEDEMAKERS M, et al. Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA)[J]. BMC Health Serv Res, 2018,18(1): 576.
[13]NATIONAL ACADEMIES OF SCIENCES E A M, DIVISION H A M, SERVICES B O H C, et al. An Evidence Framework for Genetic Testing[M]. Washington (DC): National Academies Press (US), 2017.
[14]MARSH K, IJZERMAN M, THOKALA P, et al. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force[J]. Value Health, 2016,19(2): 125-137.
[15]BALTUSSEN R, YOUNGKONG S, PAOLUCCI F, et al. Multi-criteria decision analysis to prioritize health interventions: Capitalizing on first experiences[J]. Health Policy, 2010,96(3): 262-264.
[16]THOKALA P, DEVLIN N, MARSH K, et al. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force[J]. Value Health, 2016,19(1): 1-13.
[17]Le GALES C, MOATTI J P. Searching for consensus through multi-criteria decision analysis. Assessment of screening strategies for hemoglobinopathies in southeastern France[J]. Int J Technol Assess Health Care, 1990,6(3): 430-449.
[18]MUSSEN F, SALEK S, WALKER S. A quantitative approach to benefit-risk assessment of medicines--part 1: the development of a new model using multi-criteria decision analysis; part 2: the practical application of a new model[J]. Pharmacoepidemiol Drug Saf, 2007,16 Suppl 1: S42-S46.
[19]GOETGHEBEUR M M, WAGNER M, KHOURY H, et al. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal[J]. Med Decis Making, 2012,32(2): 376-388.
[20]ANGELIS A, LINCH M, MONTIBELLER G, et al. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework[J]. Soc Sci Med, 2020,246: 112595.
[21]OSBORNE R H, De ABREU L R, DALTON A, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study[J]. Value Health, 2007,10(6): 451-456.
[22]KARNON J, TOLLEY K, OYEE J, et al. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom[J]. Curr Med Res Opin, 2008,24(6): 1609-1621.